肾移植术后应用他克莫司的临床观察

目的 观察他克莫司（ＦＫ５０６）作为免疫抑制剂的有效性和安全性。方法 将首次接受同种异体肾移植的３５例患者随机分为２组，一组给予他克莫司，硫唑嘌呤（或霉酚酸酯）和泼尼松（ＦＫ５０６组），另一组给予环孢素Ａ、硫唑嘌呤（或霉酚酸酯）及泼尼松（ＣｓＡ组），观察２个组的免疫抑制效果及药物的副作用。结果 ＣｓＡ组和ＦＫ５０６组的人／肾１年存活率分别为１００．０％／９３／３％和９５．０％／９５．０％；两组肝和

Clinical uSe of tacrolimus(FK506)in renal transplantation

Objectives To compare the effect and safety of tacrolimus (FK506) with cyclosporin (CsA) in renal transplantation. Methods A total of 35 first cadaveric kidney transplant recipients were randomized to receive FK506 based ( n =20) or CsA based ( n =15) triple therapy after transplantation. The immunosuppressive effects and side reactions were observed in both two groups. Results The 1 year person/graft survival rate in FK506 and CsA groups was 100.0% and 93.3%, 95.0% and 95.0% , respectively .The differences in liver and renal function, blood glucose and blood potassium between the two groups were not significant ( P > 0.05 ). In FK506 group blood lipid and systolic pressure were obviously lower and the incidence of alkaline phosphatase higher than in CsA group ( P < 0.05 ). Conclusions Tacrolimus is a safe and effective immunosuppressive agent. Combined use of FK506 with MMF may decrease the episodes of acute rejection.